Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Stoke Therapeutics (STOK) Operating Expenses (2022 - 2025)

Stoke Therapeutics has reported Operating Expenses over the past 4 years, most recently at $215.2 million for Q4 2025.

  • Quarterly results put Operating Expenses at $215.2 million for Q4 2025, up 288.7% from a year ago — trailing twelve months through Dec 2025 was $263.5 million (up 2226.01% YoY), and the annual figure for FY2025 was $205.0 million, up 1754.51%.
  • Operating Expenses for Q4 2025 was $215.2 million at Stoke Therapeutics, up from $53.7 million in the prior quarter.
  • Over the last five years, Operating Expenses for STOK hit a ceiling of $215.2 million in Q4 2025 and a floor of -$114.1 million in Q4 2024.
  • Median Operating Expenses over the past 4 years was $30.5 million (2022), compared with a mean of $30.7 million.
  • Biggest five-year swings in Operating Expenses: crashed 452.14% in 2024 and later surged 288.7% in 2025.
  • Stoke Therapeutics' Operating Expenses stood at $30.4 million in 2022, then increased by 6.39% to $32.4 million in 2023, then crashed by 452.14% to -$114.1 million in 2024, then surged by 288.7% to $215.2 million in 2025.
  • The last three reported values for Operating Expenses were $215.2 million (Q4 2025), $53.7 million (Q3 2025), and -$3.8 million (Q2 2025) per Business Quant data.